We are live on ! Find out more
ENSC icon

Ensysce Biosciences
ENSC

15 hedge funds and large institutions have $6.23M invested in Ensysce Biosciences in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

25% more funds holding

Funds holding: 12 → 15 (+3)

0% more ownership

Funds ownership: 0% → 0.01% (+0%)

61% less capital invested

Capital invested by funds: $15.9M → $6.23M (-$9.64M)

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

Holders
15
Holders Change
+3
Holders Change %
+25%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
1
Reduced
4
Closed
2
Calls
$225K
Puts
–
Net Calls
+$225K
Net Calls Change
+$225K

Top Buyers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
+$3.44M
2
Renaissance Technologies
Renaissance Technologies
New York
+$529K
3
BlackRock
BlackRock
New York
+$430K
4
PIA
Powell Investment Advisors
Florida
+$92.5K
5
VF
Virtu Financial
New York
+$46.3K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$802K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$331K
3
Jane Street
Jane Street
New York
-$79K
4
TRCT
Tower Research Capital (TRC)
New York
-$39.7K
5
ECM
Evergreen Capital Management
Washington
-$6.61K
Name Holding Trade Value Shares
Change 		Change in
Stake
HVCM
1
HG Vora Capital Management
New York
$2.81M – – –
AFM
2
Anson Funds Management
Texas
$2.14M +$3.44M +521 New
Renaissance Technologies
3
Renaissance Technologies
New York
$328K +$529K +80 New
BlackRock
4
BlackRock
New York
$267K +$430K +65 New
Stifel Financial
5
Stifel Financial
Missouri
$247K – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$140K -$331K -50 -60%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$125K +$19.8K +3 +11%
PIA
8
Powell Investment Advisors
Florida
$57K +$92.5K +14 New
State Street
9
State Street
Massachusetts
$41K – – –
VF
10
Virtu Financial
New York
$28K +$46.3K +7 New
ECM
11
Evergreen Capital Management
Washington
$13K -$6.61K -1 -25%
CAM
12
Cresset Asset Management
Illinois
$13K – – –
TRCT
13
Tower Research Capital (TRC)
New York
$12K -$39.7K -6 -67%
UBS Group
14
UBS Group
Switzerland
$9K -$6.61K -1 -33%
WAM
15
Wolverine Asset Management
Illinois
$5K – – –
Goldman Sachs
16
Goldman Sachs
New York
– -$802K -47 Closed
Jane Street
17
Jane Street
New York
– -$79K -5 Closed
JP Morgan Chase
18
JP Morgan Chase
New York
– -$6K – –

ENSC Hedge Fund Activity: Q1 2022 in Review

15 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Ensysce Biosciences (ENSC) for Q1 2022, worth a combined $6.23M — down 61% from $15.9M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ENSC positions and 2 closed out — a net gain of 3 holders — while 1 added to existing stakes and 4 trimmed.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $3.44M. The largest seller was Goldman Sachs, exiting entirely with an estimated $802K sold.

  • 15 institutional investors held Ensysce Biosciences (ENSC) as of Q1 2022, up from 12 in Q4 2021.
  • Funds reported $6.23M of Ensysce Biosciences stock for Q1 2022, down 61% quarter-over-quarter.
  • 5 funds opened new Ensysce Biosciences positions in Q1 2022 and 2 closed out, a net change of +3 holders.
  • The largest Ensysce Biosciences buyer in Q1 2022 was Anson Funds Management, an estimated $3.44M added.
  • The largest Ensysce Biosciences seller in Q1 2022 was Goldman Sachs, an estimated $802K sold.

Based on aggregated 13F filings for Q1 2022.